AR044519A1 - Derivados de piridin-tiazol amina y de pirimidin-tiazol amina - Google Patents

Derivados de piridin-tiazol amina y de pirimidin-tiazol amina

Info

Publication number
AR044519A1
AR044519A1 ARP040101467A ARP040101467A AR044519A1 AR 044519 A1 AR044519 A1 AR 044519A1 AR P040101467 A ARP040101467 A AR P040101467A AR P040101467 A ARP040101467 A AR P040101467A AR 044519 A1 AR044519 A1 AR 044519A1
Authority
AR
Argentina
Prior art keywords
alkyl
amino
alkoxy
nitrogen
group
Prior art date
Application number
ARP040101467A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR044519A1 publication Critical patent/AR044519A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen composiciones farmacéuticas que contienen los compuestos y un procedimiento para preparar los compuestos. Reivindicación 1: Un compuesto de la fórmula (1) en forma libre o de sal, en donde R1 es alquilcarbonilo C1-8 opcionalmente substituido por halo, hidroxi, ciano, amino, carboxi, alquilo C1-8, alcoxi C1-8, haloalquilo C1-8, alquilamino C1-8, di(alquil C1-8)amino, di(alquil C1-8)aminocarbonilo, alquilcarbonilo C1-8,alcoxicarbonilo C1-8, un carbociclo C3-15, o por un anillo heterocíclico de 5 o 6 miembros que tiene uno o más átomos heterogéneos en el anillo seleccionados del grupo que consiste de oxígeno, nitrógeno y azufre, o R1 es un anillo heterocíclico de 5 o 6 miembros heterocíclico que tiene uno o más átomos heterogéneos seleccionados del grupo que consiste de oxígeno, nitrógeno y azufre, o R1 es aminocarbonilo opcionalmente substituido por un anillo carbociclo C3-15 o por un anillo heterocíclico de 5 o 6 miembros teniendo uno o más átomos heterogéneos en el anillo seleccionados del grupo que consiste de oxígeno, nitrógeno y azufre, o R1 es -CO-NRxRy, en donde Rx y Ry junto con el nitrógeno al cual están unidos forman un anillo N-heterocíclico de 5 a 12 miembros incluyendo opcionalmente uno o más átomos heterogéneos seleccionados del grupo que consiste de oxígeno, nitrógeno y azufre, o R1 es alquilaminocarbonilo C1-8 o cicloaIquiIaminocarbonilo C3-8 en cualquier caso opcionalmente substituido en el grupo alquilo por halo, hidroxi, ciano, amino, carboxi, alquilo C1-8, alcoxi C1-8, alcoxi C1-8 hidroxi-substituido, haloalquilo C1-8, alquilamino C1-8, di(C1-C8alquil C1-8)amino, di(alquil C1-8)amino-carbonilo, alcoxicarbonilo C1-8, un carbociclo C3-15, un anillo heterocíclico de 5 o 6 miembros que tiene uno o más átomos heterogéneos seleccionados del grupo que consiste de oxígeno, nitrógeno y azufre, o alquilaminocarbonilo C1-8 opcionalmente substituido por hidroxi, o R1 es alquilaminocarbonilo o C1-8 cicloalquilaminocarbonilo C3- 8 en cualquier caso opcionalmente substituido por aminocarbonilo opcionalmente substituido un anillo heterocíclico de 5 o 6 miembros, teniendo uno o más átomos heterogéneos seleccionados del grupo que consiste de oxígeno, nitrógeno y azufre, o R1 es hidrógeno o alquilo C1-8; R2 es alquilo C1-3; Y es carbono o nitrógeno; y cuando R1 es alquilcarbonilo C1-8 no substituido e Y es carbono entonces R3 es halógeno, hidroxi, ciano, amino, carboxi, -SO2NH2, alquilo C1-8, alcoxi C1-8, C1-C8haloalquilo C1-8, amino-alquilo C1-8, amino-alcoxi C1-8, alquilaminocarbonilo C1-8, di(alquil C1-8)amino, di(alquil C1-8)aminocarbonilo, di(alquil C1-8)amino-alquilo C1-8, di(alquil C1-8)amino-alcoxi C1-8, aminocarbonilo, alcoxicarbonilo C1-8, carboxi-alquilo C1-8, carboxi-alcoxi C1-8, un carbociclo C3-15, un anillo heterocíclico de 5 o 6 miembros, teniendo uno o más átomos heterogéneos seleccionados del grupo que consiste de oxígeno, nitrógeno y azufre, o alquilamino C1-8 opcionalmente substituido por hidroxi o di(alquil C1-8)amino, y R4 es hidrógeno, halógeno, hidroxi, ciano, amino, carboxi, -SO2NH2, alquilo C1-8, C1-C8alcoxi C1-8, haloalquilo C1-8, amino-alquilo C1-8, amino-alcoxi C1-8, alquilaminocarbonilo C1-8, di(alquil C1-8)amino, di(alquil C1-8)aminocarbonilo, di(alquil C1-8)amino-alquilo C1-8, di(alquil C1-8)aminoalcoxi C1-8, aminocarbonilo, alcoxicarbonilo C1-8, carboxi-alquilo C1-8, carboxi-alcoxi C1-8, un carbociclo C3-15, un anillo heterocíclico de 5 o 6 miembros, teniendo uno o más átomos heterogéneos seleccionados del grupo que consiste de oxígeno, nitrógeno y azufre, o alquilamino opcionalmente substituido por hidroxi o di(alquil C1-8)amino, de otra manera R3 y R4 son cada uno independientemente hidrógeno, halo, hidroxi, ciano, amino, carboxi, alquilsulfanilo C1-8, alquilsulfinilo C1-8, alquilsulfonilo C1-8, -SO2NH2, alquilo C1-8, haloalquilo C1-8, amino-alquilo C1-8, amino-alcoxi C1-8, alquilaminocarbonilo C1-8, di(C1-C8alquil C1-8)aminocarbonilo, di(alquil C1- 8)amino-alquilo C1-8, di(alquil C1-8)amino-alcoxi C1-8, acilamino C1-8, aminocarbonilo, alcoxicarbonilo C1-8, carboxi-alquilo C1-8, carboxi-alcoxi C1-8, un C3-C15 carbociclo C3-15, un anillo heterocíclico de 5 o 6 miembros, teniendo uno o más átomos heterogéneos seleccionados del grupo que consiste de oxígeno, nitrógeno y azufre, alquilamino C1-8 o di(alquil C1-8)amino cada uno estando opcionalmente substituido por amino, hidroxi, di(alquil C1-8)amino o un anillo heterocíclico de 5 o 6 miembros, teniendo uno o más átomos heterogéneos seleccionados del grupo que consiste de oxígeno, nitrógeno y azufre, o alcoxi C1-8 opcionalmente substituido por un anillo heterocíclico de 5 o 6 miembros, teniendo uno o más átomos heterogéneos seleccionados del grupo que consiste de oxígeno, nitrógeno y azufre.
ARP040101467A 2003-05-02 2004-04-29 Derivados de piridin-tiazol amina y de pirimidin-tiazol amina AR044519A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0310234 2003-05-02

Publications (1)

Publication Number Publication Date
AR044519A1 true AR044519A1 (es) 2005-09-14

Family

ID=33397059

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040101467A AR044519A1 (es) 2003-05-02 2004-04-29 Derivados de piridin-tiazol amina y de pirimidin-tiazol amina

Country Status (28)

Country Link
US (3) US20070032487A1 (es)
EP (2) EP1622897B1 (es)
JP (1) JP4510807B2 (es)
KR (1) KR100725885B1 (es)
CN (2) CN101648949A (es)
AR (1) AR044519A1 (es)
AT (1) ATE445614T1 (es)
AU (2) AU2004234068B2 (es)
BR (1) BRPI0410037B8 (es)
CA (1) CA2524401C (es)
CL (1) CL2004000917A1 (es)
DE (1) DE602004023602D1 (es)
EC (1) ECSP056127A (es)
ES (2) ES2546851T3 (es)
HK (1) HK1091810A1 (es)
IL (1) IL171536A (es)
IS (1) IS8152A (es)
MA (1) MA27774A1 (es)
MX (1) MXPA05011740A (es)
NO (1) NO20055714L (es)
PE (1) PE20050147A1 (es)
PL (1) PL1622897T3 (es)
PT (1) PT1622897E (es)
RU (2) RU2481346C2 (es)
TN (1) TNSN05278A1 (es)
TW (1) TW200519106A (es)
WO (1) WO2004096797A1 (es)
ZA (1) ZA200508603B (es)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
TW200533357A (en) 2004-01-08 2005-10-16 Millennium Pharm Inc 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
SE0402735D0 (sv) * 2004-11-09 2004-11-09 Astrazeneca Ab Novel compounds
US7786132B2 (en) * 2004-12-17 2010-08-31 Amgen Inc. Aminopyrimidine compounds and methods of use
US20060178388A1 (en) * 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
US7879888B2 (en) * 2005-05-24 2011-02-01 Merck Serono Sa Thiazole derivatives and use thereof
EP1888546B1 (en) 2005-05-24 2015-07-08 Merck Serono SA Thiazole derivatives and use thereof
AU2006258101A1 (en) * 2005-06-09 2006-12-21 Merck Sharp & Dohme Corp. Inhibitors of checkpoint kinases
GB2431156A (en) * 2005-10-11 2007-04-18 Piramed Ltd 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase
ES2389062T3 (es) * 2006-01-18 2012-10-22 Amgen, Inc Compuestos de tiazol como inhibidores de proteína cinasa B (PKB)
BRPI0706610A2 (pt) * 2006-01-18 2011-04-05 Siena Biotech Spa moduladores de receptores alfa 7 nicotìnico acetilcolina e usos terapêuticos destes
US20090029997A1 (en) * 2006-01-23 2009-01-29 Laboratoires Serono Sa Thiazole Derivatives and Use Thereof
US8217037B2 (en) * 2006-04-07 2012-07-10 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers
CN101484452A (zh) * 2006-05-03 2009-07-15 阿斯利康(瑞典)有限公司 噻唑衍生物及其作为抗肿瘤药物的用途
GB0612630D0 (en) * 2006-06-26 2006-08-02 Novartis Ag Organic compounds
US8268818B2 (en) 2006-09-01 2012-09-18 Vertex Pharmaceuticals Incorporated Inhibitors of C-MET and uses thereof
GB0620059D0 (en) 2006-10-10 2006-11-22 Ucb Sa Therapeutic agents
GB0620818D0 (en) 2006-10-19 2006-11-29 Ucb Sa Therapeutic agents
US9370508B2 (en) * 2007-02-20 2016-06-21 Novartis Ag Imidazoquinolines as dual lipid kinase and mTOR inhibitors
TW200906825A (en) * 2007-05-30 2009-02-16 Scripps Research Inst Inhibitors of protein kinases
JP5616220B2 (ja) 2007-06-01 2014-10-29 ザ トラスティーズ オブ プリンストン ユニバーシティ 宿主細胞代謝経路の調節によるウイルス感染治療
AU2008276512A1 (en) * 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of PKB
AU2008276521B2 (en) 2007-07-17 2011-11-03 Amgen Inc. Heterocyclic modulators of PKB
PA8809001A1 (es) 2007-12-20 2009-07-23 Novartis Ag Compuestos organicos
CN101939319A (zh) * 2007-12-20 2011-01-05 诺瓦提斯公司 联噻唑衍生物、它们的制备方法以及它们作为药物的用途
US9029411B2 (en) 2008-01-25 2015-05-12 Millennium Pharmaceuticals, Inc. Thiophenes and uses thereof
EP2253618A1 (en) 2008-02-27 2010-11-24 Takeda Pharmaceutical Company Limited Compound having 6-membered aromatic ring
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
CN102395585A (zh) * 2009-01-30 2012-03-28 米伦纽姆医药公司 杂芳基化合物和其作为pi3k抑制剂的用途
WO2010125799A1 (ja) * 2009-04-27 2010-11-04 塩野義製薬株式会社 Pi3k阻害活性を有するウレア誘導体
PL2424864T3 (pl) * 2009-04-30 2015-05-29 Glaxo Group Ltd Podstawione oksazolami indazole jako inhibitory kinazy pi3
EP2440556A1 (en) * 2009-06-10 2012-04-18 Vertex Pharmaceuticals Incorporated Inhibitors of phosphatidylinositol 3-kinase
AU2010268058A1 (en) 2009-07-02 2012-01-19 Novartis Ag 2-carboxamide cycloamino ureas useful as PI3K inhibitors
US8293753B2 (en) * 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
EP2492269A4 (en) 2009-10-19 2013-08-07 Taisho Pharmaceutical Co Ltd aminothiazole
CA2788678C (en) 2010-02-03 2019-02-26 Signal Pharmaceuticals, Llc Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors
JP2013533318A (ja) 2010-08-11 2013-08-22 ミレニアム ファーマシューティカルズ， インコーポレイテッド ヘテロアリールおよびその使用
EA201390214A1 (ru) 2010-08-11 2013-07-30 Милленниум Фармасьютикалз, Инк. Гетероарилы и их применение
US9062038B2 (en) 2010-08-11 2015-06-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
KR20140091462A (ko) 2010-10-13 2014-07-21 밀레니엄 파머슈티컬스 인코퍼레이티드 헤테로아릴 및 그의 용도
AU2015203865B2 (en) * 2010-11-08 2016-11-03 Novartis Ag Use of 2-carboxamide cycloamino urea derivatives in the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family members
MX360157B (es) * 2010-11-08 2018-10-24 Novartis Ag Uso de derivados de 2-carboxamida-cicloamino-urea en el tratamiento de enfermedades dependientes de egfr o de enfermedades que han adquirido resistencia a los agentes que tienen como objetivo los miembros de la familia egfr.
UA112539C2 (uk) * 2011-03-03 2016-09-26 Новартіс Аг Спосіб одержання похідних 2-карбоксамідциклоаміносечовини
CA2833962A1 (en) * 2011-04-25 2012-11-01 Novartis Ag Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor
EA030465B1 (ru) 2011-07-01 2018-08-31 Новартис Аг Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака
CA2843887A1 (en) 2011-08-03 2013-02-07 Signal Pharmaceuticals, Llc Identification of gene expression profile as a predictive biomarker for lkb1 status
US9926309B2 (en) 2011-10-05 2018-03-27 The Board Of Trustees Of The Leland Stanford Junior University Pi-kinase inhibitors with anti-infective activity
JP2015512416A (ja) * 2012-03-30 2015-04-27 ノバルティス アーゲー 神経芽細胞腫、ユーイング肉腫または横紋筋肉腫の治療に使用するための化合物
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
EP2742940B1 (en) 2012-12-13 2017-07-26 IP Gesellschaft für Management mbH Fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-l-aza-bicyclo-[2.2.2]octane for adminstration once daily, twice daily or thrice daily
TWI628170B (zh) 2013-02-05 2018-07-01 先正達合夥公司 植物生長調節化合物
AU2014254050B2 (en) 2013-04-17 2018-10-04 Signal Pharmaceuticals, Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
MX2015014590A (es) 2013-04-17 2016-03-03 Signal Pharm Llc Tratamiento de cancer con dihidropirazino-pirazinas.
NZ631082A (en) 2013-04-17 2017-06-30 Signal Pharm Llc Methods for treating cancer using tor kinase inhibitor combination therapy
BR112015026238A8 (pt) 2013-04-17 2019-12-24 Signal Pharm Llc composto dihidropirazino-pirazina, composição farmacêutica que o compreende, uso do composto, métodos para inibir ou medir a fosforilação e para inibir a atividade da proteína quinase, bem como kit
US9474757B2 (en) 2013-04-17 2016-10-25 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy
BR112015026257B1 (pt) 2013-04-17 2022-12-20 Signal Pharmaceuticals, Llc Uso de um composto dihidropirazino-pirazina e enzalutamida, composição farmacêutica que os compreende, e kit
MX2015014455A (es) 2013-04-17 2016-07-21 Signal Pharm Llc Terapia de combinacion que comprende un inhibidor de tor cinasa y n-(3-(5-fluoro-2-(4-(2-metoxietoxi)fenilamino)pirimidin-4-ilamino )fenil)acrilamida para tratar cancer.
CA2912627C (en) 2013-05-29 2022-03-15 Signal Pharmaceuticals, Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
WO2015160880A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
CN104744376A (zh) * 2015-03-14 2015-07-01 长沙深橙生物科技有限公司 一种2-异丙基嘧啶衍生物的制备方法
CN104803921A (zh) * 2015-03-14 2015-07-29 长沙深橙生物科技有限公司 一种苯取代嘧啶衍生物的制备方法
EP3419980A4 (en) 2016-02-26 2019-07-03 The Board of Trustees of the Leland Stanford Junior University INHIBITORS OF PI-KINASE WITH ANTI-INFECTIOUS ACTIVITY
KR20200019229A (ko) 2017-06-22 2020-02-21 셀진 코포레이션 B형 간염 바이러스 감염을 특징으로 하는 간세포 암종의 치료
EP3740484B1 (en) * 2018-01-15 2024-09-11 Aucentra Therapeutics Pty Ltd 5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents
AU2019324089B2 (en) 2018-08-21 2024-06-13 Kyorin Pharmaceutical Co., Ltd. Bicyclic heteroaromatic ring derivative
WO2021142006A1 (en) * 2020-01-07 2021-07-15 Disarm Therapeutics, Inc. Inhibitors of sarm1
TW202334117A (zh) 2020-08-24 2023-09-01 美商達薩瑪治療公司 Ｓａｒｍ１之抑制劑

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1219606A (en) 1968-07-15 1971-01-20 Rech S Et D Applic Scient Soge Quinuclidinol derivatives and preparation thereof
GB8302591D0 (en) * 1983-01-31 1983-03-02 Fujisawa Pharmaceutical Co Thiazole derivatives
US4649146A (en) 1983-01-31 1987-03-10 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivatives and pharmaceutical composition comprising the same
DE3703435A1 (de) * 1987-02-05 1988-08-18 Thomae Gmbh Dr K Neue thiazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE68916198T2 (de) 1988-04-15 1994-09-22 Taiho Pharmaceutical Co Ltd Carbamoyl-2-Pyrrolidinonverbindungen.
GB8916480D0 (en) 1989-07-19 1989-09-06 Glaxo Group Ltd Chemical process
GB8923590D0 (en) 1989-10-19 1989-12-06 Pfizer Ltd Antimuscarinic bronchodilators
CA2038379C (en) 1990-03-22 2002-11-05 Norma G. Delaney Trifluoromethyl mercaptan and mercaptoacyl derivatives and method of using same
US5451700A (en) 1991-06-11 1995-09-19 Ciba-Geigy Corporation Amidino compounds, their manufacture and methods of treatment
GB9301000D0 (en) 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
GB9414208D0 (en) 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
GB9414193D0 (en) 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
GB9622386D0 (en) 1996-10-28 1997-01-08 Sandoz Ltd Organic compounds
JP2001505585A (ja) 1996-12-16 2001-04-24 藤沢薬品工業株式会社 新規アミド化合物およびそれらの一酸化窒素シンターゼ阻害剤としての用途
US6187797B1 (en) 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
TW528755B (en) 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
US6166037A (en) 1997-08-28 2000-12-26 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
DE69821132T2 (de) 1997-10-27 2004-10-21 Takeda Chemical Industries Ltd 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes
GB9723589D0 (en) 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
GB9723566D0 (en) 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
GB9723590D0 (en) 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
AR017457A1 (es) 1998-02-14 2001-09-05 Glaxo Group Ltd Compuestos derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol, procesos para su preparacion, composiciones que los contienen y su uso en terapia para el tratamiento de enfermedades inflamatorias.
EP1087951B9 (en) 1998-06-18 2006-09-13 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
GB9813540D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813535D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813565D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
CN1313861A (zh) 1998-06-23 2001-09-19 葛兰素集团有限公司 2－(嘌呤－9－基)－四氢呋喃－3,4－二醇衍生物
AU8180398A (en) 1998-06-30 2000-01-17 Dow Global Technologies Inc. Polymer polyols and a process for the production thereof
EP1121372B1 (en) 1998-10-16 2006-06-28 Pfizer Limited Adenine derivatives
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
AU765473B2 (en) * 1999-04-23 2003-09-18 Takeda Pharmaceutical Company Limited 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof
CZ20013940A3 (cs) 1999-05-04 2002-04-17 Schering Corporation Piperazinové deriváty uľitečné jako CCR5 antagonisté
ATE299866T1 (de) 1999-05-04 2005-08-15 Schering Corp Piperidinderivate verwendbar als ccr5 antagonisten
YU25500A (sh) 1999-05-11 2003-08-29 Pfizer Products Inc. Postupak za sintezu analoga nukleozida
GB9913932D0 (en) 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
US6322771B1 (en) 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
HUP0202682A3 (en) * 1999-09-10 2003-03-28 Merck & Co Inc Tyrosine kinase inhibitors, pharmaceutical compositions containing them and their use
CO5180581A1 (es) 1999-09-30 2002-07-30 Pfizer Prod Inc Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia
GB9924363D0 (en) 1999-10-14 1999-12-15 Pfizer Central Res Purine derivatives
GB9924361D0 (en) 1999-10-14 1999-12-15 Pfizer Ltd Purine derivatives
GB0003960D0 (en) 2000-02-18 2000-04-12 Pfizer Ltd Purine derivatives
CN100355751C (zh) * 2000-03-29 2007-12-19 西克拉塞尔有限公司 2－取代的4－杂芳基－嘧啶、其组合物及其用途
TWI227240B (en) 2000-06-06 2005-02-01 Pfizer 2-aminocarbonyl-9H-purine derivatives
GB0015727D0 (en) 2000-06-27 2000-08-16 Pfizer Ltd Purine derivatives
DE20122417U1 (de) 2000-06-27 2005-08-04 Laboratorios S.A.L.V.A.T., S.A., Esplugues De Llobregat Von Arylalkylaminen abgeleitete Carbamate
GB0015876D0 (en) 2000-06-28 2000-08-23 Novartis Ag Organic compounds
DE10038639A1 (de) 2000-07-28 2002-02-21 Schering Ag Nichtsteroidale Entzündungshemmer
ES2292604T5 (es) 2000-08-05 2015-06-01 Glaxo Group Limited Éster S-fluorometílico del ácido 6 ,9 -difluoro-17 -[(2-furanilcarbonil)oxi]-11 -hidroxi-16 -metil-3-oxo-androsta-1,4-dien-17 -carbotioico como agente antiinflamatorio
GB0022695D0 (en) 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
KR100600550B1 (ko) 2000-10-20 2006-07-13 에자이 가부시키가이샤 질소 함유 방향환 유도체
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
JP4445704B2 (ja) 2000-12-22 2010-04-07 アルミラル・ソシエダッド・アノニマ キヌクリジンカルバメート誘導体およびｍ３アンダゴニストとしてのそれらの使用
UA75626C2 (en) 2000-12-28 2006-05-15 Almirall Prodesfarma Ag Quinuclidine derivatives and medicinal compositions containing the same
EP1241176A1 (en) 2001-03-16 2002-09-18 Pfizer Products Inc. Purine derivatives for the treatment of ischemia
CN1302007C (zh) 2001-04-30 2007-02-28 葛兰素集团有限公司 具有抗炎性的在17.α位上具有环酯基的雄甾烷的17.β.－硫代羧酸酯衍生物
ATE315555T1 (de) 2001-05-11 2006-02-15 Pfizer Prod Inc Thiazolderivate und ihre verwendung als cdk- inhibitoren
WO2002096462A1 (en) 2001-05-25 2002-12-05 Pfizer Inc. An adenosine a2a receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases
ATE399174T1 (de) 2001-06-12 2008-07-15 Glaxo Group Ltd Neue anti inflammatorische 17.alpha.- heterozyklische ester von 17.beta.-carbothioat androstan derivativen
DK2327767T3 (en) 2001-06-21 2015-07-27 Basf Enzymes Llc nitrilases
HUP0401748A3 (en) * 2001-08-13 2011-03-28 Janssen Pharmaceutica Nv 2-amino-4,5-trisubstituted thiazolyl derivatives, process for their preparation and pharmaceutical compositions containing them
US7265134B2 (en) 2001-08-17 2007-09-04 Merck & Co., Inc. Tyrosine kinase inhibitors
DE60217140T2 (de) 2001-09-28 2007-04-19 Cyclacel Ltd. N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-n-phenylamine als antiproliferative verbindungen
BR0212983A (pt) 2001-10-17 2004-10-13 Ucb Sa Composto, uso do composto, e, intermediários de sìntese
GB0125259D0 (en) 2001-10-20 2001-12-12 Glaxo Group Ltd Novel compounds
AR037517A1 (es) 2001-11-05 2004-11-17 Novartis Ag Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
AU2002356759A1 (en) 2001-12-01 2003-06-17 Glaxo Group Limited 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents
CN1832948B (zh) 2001-12-20 2011-06-15 基耶西药品股份公司 1-烷基-1-氮*双环[2.2.2]辛烷氨基甲酸酯衍生物及其用作蕈毒碱受体拮抗剂的用途
AU2003202044A1 (en) 2002-01-15 2003-09-09 Glaxo Group Limited 17.alpha-cycloalkyl/cycloylkenyl esters of alkyl-or haloalkyl-androst-4-en-3-on-11.beta.,17.alpha.-diol 17.beta.-carboxylates as anti-inflammatory agents
WO2003062259A2 (en) 2002-01-21 2003-07-31 Glaxo Group Limited Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents
GB0202216D0 (en) 2002-01-31 2002-03-20 Glaxo Group Ltd Novel compounds
MY156407A (en) 2002-02-28 2016-02-26 Novartis Ag 5-phenylthiazole derivatives and use as p13 kinase inhibitors
CA2477764A1 (en) 2002-03-26 2003-10-09 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
PT1490062E (pt) 2002-03-26 2008-01-30 Boehringer Ingelheim Pharma Miméticos de glucocorticóides, métodos para a sua preparação, composições farmacêuticas e suas utilizações
ATE381336T1 (de) 2002-04-10 2008-01-15 Univ Virginia Verwendung von a2a adenosin rezeptor agonisten und anti-pathogene mittel enthaltenden kombinationen zur behandlung von entzündungskrankheiten
ES2206021B1 (es) 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
DE10224888A1 (de) 2002-06-05 2003-12-24 Merck Patent Gmbh Pyridazinderivate
US7074806B2 (en) 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
DE10225574A1 (de) 2002-06-10 2003-12-18 Merck Patent Gmbh Aryloxime
DE10227269A1 (de) 2002-06-19 2004-01-08 Merck Patent Gmbh Thiazolderivate
US7153968B2 (en) 2002-06-25 2006-12-26 Merck Frosst Canada, Ltd. 8-(biaryl)quinoline PDE4 inhibitors
ES2204295B1 (es) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
AU2003281219A1 (en) 2002-07-02 2004-01-23 Bernard Cote Di-aryl-substituted-ethane pyridone pde4 inhibitors
JP4503436B2 (ja) 2002-07-08 2010-07-14 ファイザー・プロダクツ・インク 糖質コルチコイド受容体のモジュレーター
PE20050130A1 (es) 2002-08-09 2005-03-29 Novartis Ag Compuestos organicos
NZ540161A (en) 2002-10-30 2008-03-28 Vertex Pharma Compositions useful as inhibitors of rock and other protein kinases
US7632858B2 (en) 2002-11-15 2009-12-15 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
GB0305152D0 (en) 2003-03-06 2003-04-09 Novartis Ag Organic compounds
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
GB0320197D0 (en) 2003-08-28 2003-10-01 Novartis Ag Organic compounds
RU2006111093A (ru) 2003-09-06 2007-10-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) Модуляторы атр-связывающих кассетных транспортеров
BRPI0506749A (pt) 2004-01-12 2007-05-22 Applied Research Systems derivados de tiazol e uso dos mesmos
SE0402735D0 (sv) 2004-11-09 2004-11-09 Astrazeneca Ab Novel compounds
EP1888546B1 (en) 2005-05-24 2015-07-08 Merck Serono SA Thiazole derivatives and use thereof
US7879888B2 (en) 2005-05-24 2011-02-01 Merck Serono Sa Thiazole derivatives and use thereof
US7655446B2 (en) 2005-06-28 2010-02-02 Vertex Pharmaceuticals Incorporated Crystal structure of Rho-kinase I kinase domain complexes and binding pockets thereof
DE102005048072A1 (de) 2005-09-24 2007-04-05 Bayer Cropscience Ag Thiazole als Fungizide
CN101331125A (zh) 2005-12-12 2008-12-24 健亚生物科技公司 N-(5-元杂芳香环)-酰胺基抗病毒化合物
GB0525671D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
US20090029997A1 (en) 2006-01-23 2009-01-29 Laboratoires Serono Sa Thiazole Derivatives and Use Thereof
GB0610243D0 (en) 2006-05-23 2006-07-05 Novartis Ag Organic compounds
TW200827368A (en) 2006-11-21 2008-07-01 Genelabs Tech Inc Amido anti-viral compounds
WO2008124000A2 (en) 2007-04-02 2008-10-16 Ligand Pharmaceuticals Incorporated Thiazole derivatives as androgen receptor modulator compounds
CA2686651C (en) 2007-05-25 2015-11-24 Abbott Gmbh & Co. Kg Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mglu2 receptor)
WO2009003009A1 (en) 2007-06-26 2008-12-31 Enanta Pharmaceuticals, Inc. Substituted pyrrolidine as anti-infectives
PT2178865E (pt) 2007-07-19 2015-11-16 Lundbeck & Co As H Amidas heterocíclicas com 5 membros e compostos relacionados
CN101939319A (zh) 2007-12-20 2011-01-05 诺瓦提斯公司 联噻唑衍生物、它们的制备方法以及它们作为药物的用途
PA8809001A1 (es) 2007-12-20 2009-07-23 Novartis Ag Compuestos organicos
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas

Also Published As

Publication number Publication date
ES2331883T3 (es) 2010-01-19
EP1622897A1 (en) 2006-02-08
RU2481346C2 (ru) 2013-05-10
US20110105535A1 (en) 2011-05-05
AU2008255157A1 (en) 2009-01-08
HK1091810A1 (en) 2007-01-26
JP4510807B2 (ja) 2010-07-28
NO20055714D0 (no) 2005-12-02
ATE445614T1 (de) 2009-10-15
BRPI0410037A (pt) 2006-04-25
US20070032487A1 (en) 2007-02-08
ZA200508603B (en) 2006-12-27
EP2157091A1 (en) 2010-02-24
US20130172349A1 (en) 2013-07-04
NO20055714L (no) 2006-02-02
KR100725885B1 (ko) 2007-06-08
ES2546851T3 (es) 2015-09-29
PT1622897E (pt) 2009-12-10
JP2006525266A (ja) 2006-11-09
ECSP056127A (es) 2006-03-01
EP1622897B1 (en) 2009-10-14
BRPI0410037B8 (pt) 2021-05-25
CL2004000917A1 (es) 2005-02-11
CA2524401C (en) 2011-11-22
KR20060009884A (ko) 2006-02-01
WO2004096797A1 (en) 2004-11-11
PL1622897T3 (pl) 2010-03-31
RU2005137358A (ru) 2006-07-27
CN1816549A (zh) 2006-08-09
US8404684B2 (en) 2013-03-26
AU2008255157B2 (en) 2011-02-03
BRPI0410037B1 (pt) 2018-01-16
IL171536A (en) 2013-02-28
MXPA05011740A (es) 2006-01-26
RU2009134044A (ru) 2011-03-20
MA27774A1 (fr) 2006-02-01
DE602004023602D1 (en) 2009-11-26
IS8152A (is) 2005-11-25
EP2157091B1 (en) 2015-06-10
TNSN05278A1 (en) 2007-07-10
CN1816549B (zh) 2010-09-29
PE20050147A1 (es) 2005-05-05
CA2524401A1 (en) 2004-11-11
AU2004234068A1 (en) 2004-11-11
RU2384580C2 (ru) 2010-03-20
CN101648949A (zh) 2010-02-17
AU2004234068B2 (en) 2008-09-11
TW200519106A (en) 2005-06-16

Similar Documents

Publication Publication Date Title
AR044519A1 (es) Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
ES2422204T3 (es) Novedosos derivados de imidazolidin-2-ona como moduladores selectivos de receptor de andrógenos (SARMS)
CO6231035A2 (es) Novedoso compuesto heteromonociclico que tiene propiedades superiores como agente farmaceutico
CO6160237A2 (es) Pirazinonas y pirazinoles sustituidos y composiciones que los comprenden
CO5700774A2 (es) Derivados de triazol como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa-1
CO5700820A2 (es) Derivados de dioxan-2-alquilcarbamatos, su preparacion y su aplicacion en terapeutica
AR038703A1 (es) Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3
ECSP099324A (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
MX2009010024A (es) Nuevo compuesto de adenina.
CR9421A (es) Compuestos heterociclicos fusionados
PE20130155A1 (es) Derivados de ariletinilo
CO6190521A2 (es) Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta -9 desaturasa
ES2530943T3 (es) Derivados de la cromenona con actividad antitumoral
ECSP055974A (es) Síntesis de cloruros de 4 amino-2-butenoil y su uso en la preparación de 3-ciano quinolinas
EA200701176A1 (ru) Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их
TW200615267A (en) New bicyclic antibiotics
ECSP10010060A (es) Derivados de pirazol sustituídos
CO6160296A2 (es) Derivados de acido benzoazepin-oxi-acetico como agonistas de receptores activados por proliferador de peroxisona delta usados para incrementar la lipoproteina de alta densidad-colesterol-colesterol reducir la lipoproteina de baja densidad-colesterol
AR066691A1 (es) Compuestos espiro heterociclicos derivados de imidazol. composiciones farmaceuticas.
AR054369A1 (es) Compuestos de imidazol condensado y su uso como inhibidores de aldosterona sintasa
CO6231002A2 (es) Compuestos utiles como ligandos para tomar imagenes de inervacion cardiaca
ECSP034865A (es) Resolución óptica de (1-benzilo-4-metilopiperidina-3-il)-metilamina y su uso para la preparación de derivados de pirrolo 2,3-pirimidina como inhibidores de proteina quinasas
ATE496043T1 (de) 3-heteroaryl (amino bzw. amido)-1- (biphenyl bzw. phenylthiazolyl) carbonylpiperdinderivate als orexinrezeptor-inhibitoren
UY30897A1 (es) Derivados de pentafluorotiobenzamidoacetonitrilo, composiciones conteniéndolos y aplicaciones

Legal Events

Date Code Title Description
FA Abandonment or withdrawal